Abstract 6068
Background
Photosensitizers (PS) are commonly used in photodynamic therapy to treat skin cancer. PS molecules bind to cell membrane and damage it by singlet oxygen (SO) generated under illumination. In our laboratory, we study in vitro the processes involved in photodynamic therapy on a model bilayer lipid membranes (BLM) by measuring the boundary potential applying the Intramembrane Field Compensation Method (Sokolov and Kuz’min, Biofizika, 25:170, 1980).
Methods
This method allowed to monitor the binding of PS on BLM and damage of target molecules (TM) of SO - di-4-ANEPPS under excitation of PS by light. In present investigation, we studied the adsorption and photodynamic efficiency of new positively charged porphyrins, namely b-imidazolyl substituted porphyrin and it’s Zn(II) and In(III) complexes; and two phosphorus (V) complexes of meso-(p-pyridyl)-triphenylporphyrin bearing hydroxyl and ethoxyl axial ligands. We observed a linear dependence of the boundary potential change on the logarithm of concentrations of each PS.
Results
The photodynamic efficiency of these porphyrins was assessed by determining the rate of oxidation (R) of TM adsorbed either on the same or opposite surface of the BLM where molecules PS were present. The values R for both positions of TM were close indicating that BLM is highly permeable to singlet oxygen. The values R were proportional to surface density of the porphyrin molecules in the membrane.
Conclusions
This investigation indicate that the main factor influencing the photodynamic efficiency of the porphyrins is their adsorption on the BLM. The work was supported by the Russian Foundation for Basic Research (project 19-04-00694) and the Ministry of Education and Science of the Russian Federation in the framework of Increase Competitiveness Program of NUST «MISiS» (№ К4-2017-053).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National University of Science and Technology.
Funding
NUST-MISiS, Russian Science Foundation, Russian Academy of Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract